Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESTIGE trial in older patients with resectable pancreatic cancer
jRCTs031220351Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of gemcitabine, tegafur and paclitaxel in pancreatic cancer (PC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Jan 2023; status: recruiting.
02
Drugs
gemcitabinetegafurpaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs031220351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220351.